143 related articles for article (PubMed ID: 4901383)
1. Similarities between neurologic effects of L-dopa and of apomorphine.
Cotzias GC; Papavasiliou PS; Fehling C; Kaufman B; Mena I
N Engl J Med; 1970 Jan; 282(1):31-3. PubMed ID: 4901383
[No Abstract] [Full Text] [Related]
2. Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane.
Mena I; Court J; Fuenzalida S; Papavasiliou PS; Cotzias GC
N Engl J Med; 1970 Jan; 282(1):5-10. PubMed ID: 5307796
[No Abstract] [Full Text] [Related]
3. Injected apomorphine and orally administered levodopa in Parkinsonism.
Düby SE; Cotzias GC; Papavasiliou PS; Lawrence WH
Arch Neurol; 1972 Dec; 27(6):474-80. PubMed ID: 4563448
[No Abstract] [Full Text] [Related]
4. Levodopa in the treatment of Parkinsonism.
Cotzias GC
JAMA; 1971 Dec; 218(13):1903-8. PubMed ID: 5171066
[No Abstract] [Full Text] [Related]
5. Metabolic modification of some neurologic disorders.
Cotzias GC
JAMA; 1969 Nov; 210(7):1255-62. PubMed ID: 5394649
[No Abstract] [Full Text] [Related]
6. Parkinsonism and DOPA.
Cotzias GC; Papavasiliou PS; Gellene R; Aronson RB
Trans Assoc Am Physicians; 1968; 81():171-83. PubMed ID: 4889342
[No Abstract] [Full Text] [Related]
7. [Apomorphine in the biochemical concept of Parkinson's tremor].
Brinkmann R; Strian F
Nervenarzt; 1974 Sep; 45(9):474-6. PubMed ID: 4437688
[No Abstract] [Full Text] [Related]
8. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.
Papavasiliou PS; Cotzias GC; Düby SE; Steck AJ; Fehling C; Bell MA
N Engl J Med; 1972 Jan; 286(1):8-14. PubMed ID: 4550085
[No Abstract] [Full Text] [Related]
9. Observations on the range of efficacy of L-dopa.
Klawans HL
Confin Neurol; 1971; 33(3):133-45. PubMed ID: 4940610
[No Abstract] [Full Text] [Related]
10. Effects of L-dopa on the H-reflex in parkinsonism.
Fujita S; Cooper IS
J Am Geriatr Soc; 1971 Apr; 19(4):289-95. PubMed ID: 4936279
[No Abstract] [Full Text] [Related]
11. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.
Goodwin FK; Murphy DL; Brodie HK; Bunney WE
Biol Psychiatry; 1970 Oct; 2(4):341-66. PubMed ID: 4920729
[No Abstract] [Full Text] [Related]
12. Modification of Parkinsonism--chronic treatment with L-dopa.
Cotzias GC; Papavasiliou PS; Gellene R
N Engl J Med; 1969 Feb; 280(7):337-45. PubMed ID: 4178641
[No Abstract] [Full Text] [Related]
13. Intellectual and memory function in parkinsonian and non-parkinsonian patients treated with L-dopa.
Donnelly EF; Chase TN
Dis Nerv Syst; 1973 Feb; 34(2):119-23. PubMed ID: 4706860
[No Abstract] [Full Text] [Related]
14. [L-DOPA therapy of parkinsonism].
Refsum S
Nord Med; 1969 May; 81(18):570-1. PubMed ID: 5768311
[No Abstract] [Full Text] [Related]
15. Levo-dihydroxyphenylalanine--Parkinson's disease and manganese poisoning.
Goldman ME
IMS Ind Med Surg; 1972 Apr; 41(4):12-5. PubMed ID: 4502399
[No Abstract] [Full Text] [Related]
16. Apomorphine, pimozide, L-Dopa and the probenecid test in Huntington's chorea.
Lal S; De la Vega C; Garelis E; Sourkes TL
Psychiatr Neurol Neurochir; 1973; 76(2):113-7. PubMed ID: 4267059
[No Abstract] [Full Text] [Related]
17. Reversal by levodopa of cholinergic hypersensitivity in Parkinson's disease.
Weintraub MI; Van Woert MH
N Engl J Med; 1971 Feb; 284(8):412-5. PubMed ID: 5540479
[No Abstract] [Full Text] [Related]
18. Clinical experimentation with apomorphine in Parkinson's disease.
Castaigne P; Laplane D; Dordain G
Res Commun Chem Pathol Pharmacol; 1971 Mar; 2(2):154-8. PubMed ID: 4948431
[No Abstract] [Full Text] [Related]
19. Chronic manganism. Neurologic and laboratory studies during treatment with levodopa.
Rosenstock HA; Simons DG; Meyer JS
JAMA; 1971 Sep; 217(10):1354-8. PubMed ID: 4998860
[No Abstract] [Full Text] [Related]
20. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.
Muenter MD; Tyce GM
Mayo Clin Proc; 1971 Apr; 46(4):231-9. PubMed ID: 5573818
[No Abstract] [Full Text] [Related]
[Next] [New Search]
